These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 27411008)

  • 21. Diabesity: therapeutic options.
    Colagiuri S
    Diabetes Obes Metab; 2010 Jun; 12(6):463-73. PubMed ID: 20518802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential.
    Torekov SS; Madsbad S; Holst JJ
    Obes Rev; 2011 Aug; 12(8):593-601. PubMed ID: 21401851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of drugs in the management of diabetes mellitus.
    Das S
    J Indian Med Assoc; 2002 Jul; 100(7):434, 436, 445-7. PubMed ID: 12674168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical effectiveness of exenatide in diabetic patients waiting for bariatric surgery.
    Iglesias P; Civantos S; Vega B; Pavón I; Guijarro G; Monereo S
    Obes Surg; 2015 Mar; 25(3):575-8. PubMed ID: 25589020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (-4 db/db)*.
    Patel V; Joharapurkar A; Gandhi T; Patel K; Dhanesha N; Kshirsagar S; Dhote V; Detroja J; Bahekar R; Jain M
    J Diabetes; 2013 Jun; 5(2):163-71. PubMed ID: 22830490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes.
    Scheen AJ; Van Gaal LF
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):911-22. PubMed ID: 24731666
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The cost of polypharmacy in patients with type 2 diabetes mellitus].
    García A LM; Villarreal R E; Galicia R L; Martínez G L; Vargas D ER
    Rev Med Chil; 2015 May; 143(5):606-11. PubMed ID: 26203572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Obesity and diabetes: the links and common approaches.
    Haslam D
    Prim Care Diabetes; 2010 Jul; 4(2):105-12. PubMed ID: 20447884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exenatide. Amylin/Eli Lilly.
    Giannoukakis N
    Curr Opin Investig Drugs; 2003 Apr; 4(4):459-65. PubMed ID: 12808888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Obesity and weight management in the elderly: a focus on men.
    Han TS; Wu FC; Lean ME
    Best Pract Res Clin Endocrinol Metab; 2013 Aug; 27(4):509-25. PubMed ID: 24054928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DPP-IV-resistant, long-acting oxyntomodulin derivatives.
    Santoprete A; Capitò E; Carrington PE; Pocai A; Finotto M; Langella A; Ingallinella P; Zytko K; Bufali S; Cianetti S; Veneziano M; Bonelli F; Zhu L; Monteagudo E; Marsh DJ; Sinharoy R; Bianchi E; Pessi A
    J Pept Sci; 2011 Apr; 17(4):270-80. PubMed ID: 21294225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antidiabetic medications and polypharmacy.
    Peron EP; Ogbonna KC; Donohoe KL
    Clin Geriatr Med; 2015 Feb; 31(1):17-27, vii. PubMed ID: 25453298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing the real-world effect of laparoscopic bariatric surgery on the management of obesity-related comorbidities: A retrospective matched cohort study using a US Claims Database.
    Patkar A; Fegelman E; R Kashyap S; Brethauer S; Bour E; Yoo A; Li G
    Diabetes Obes Metab; 2017 Feb; 19(2):181-188. PubMed ID: 27684382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay.
    Niswender K
    Diabetes Obes Metab; 2010 Apr; 12(4):267-87. PubMed ID: 20380648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Oral diabetes treatment. Which substance is indicated at which time?].
    Hamann A; Morcos M; Nawroth P
    Internist (Berl); 2004 Dec; 45(12):1356-63. PubMed ID: 15536516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hot Topics in Primary Care: Considerations in the Selection of Antihyperglycemic Therapy for Older Patients With Type 2 Diabetes Mellitus: A Focus on Newer Therapies.
    Freeman J
    J Fam Pract; 2015 Dec; 64(12 Suppl):S59-66. PubMed ID: 26845016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is there a place for incretin therapies in obesity and prediabetes?
    Holst JJ; Deacon CF
    Trends Endocrinol Metab; 2013 Mar; 24(3):145-52. PubMed ID: 23415157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigational glucagon-like peptide-1 agonists for the treatment of obesity.
    Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
    Expert Opin Investig Drugs; 2016 Oct; 25(10):1167-79. PubMed ID: 27563838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience.
    Deol H; Lekkakou L; Viswanath AK; Pappachan JM
    Endocrine; 2017 Jan; 55(1):173-178. PubMed ID: 27696231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.